Pacira to Report Third Quarter 2020 Financial Results on Thursday October 29, 2020
Pacira BioSciences, Inc. (NASDAQ:PCRX) will announce its third quarter financial results on October 29, 2020, before U.S. market opening. Following this, a live conference call and webcast will be held at 8:30 a.m. ET. Participants can join by dialing 1-877-845-0779 or 1-720-545-0035 (international), using passcode 5997369. Replay options will be available for one week. Pacira is known for its non-opioid pain management solutions, especially its long-acting analgesic, EXPAREL®, and the iovera⁰ cryoanalgesia device.
- Pacira's EXPAREL® continues to position the company as a leader in non-opioid pain management.
- The company's acquisition of the iovera⁰ system enhances its product offerings.
- None.
PARSIPPANY, N.J., Oct. 20, 2020 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX) today announced that it will report its third quarter financial results before the open of the U.S. markets on Thursday, October 29, 2020. Following the release, the company will host a live conference call and webcast at 8:30 a.m. ET.
To participate in the conference call, dial 1-877-845-0779 and provide the passcode 5997369. International callers may dial 1-720-545-0035 and use the same passcode. In addition, a live audio of the conference call will be available as a webcast. Interested parties can access the event through the “Events” page on the Pacira website at investor.pacira.com.
For those unable to participate in the live call, a replay will be available at 1-855-859-2056 (domestic) or 1-404-537-3406 (international) using the passcode 5997369. The replay of the call will be available for one week from the date of the live call. The webcast will be available on the Pacira website for approximately two weeks following the call.
About Pacira
Pacira BioSciences, Inc. (NASDAQ: PCRX) is a leading provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for health care practitioners and their patients. The company’s long-acting local analgesic, EXPAREL® (bupivacaine liposome injectable suspension) was commercially launched in the United States in April 2012. EXPAREL utilizes DepoFoam®, a unique and proprietary product delivery technology that encapsulates drugs without altering their molecular structure, and releases them over a desired period of time. In April 2019, the company acquired the iovera⁰ system, a handheld cryoanalgesia device used to deliver precise, controlled doses of cold temperature only to targeted nerves. To learn more about Pacira, including the corporate mission to reduce overreliance on opioids, visit www.pacira.com.
FAQ
When will Pacira BioSciences report its Q3 financial results for 2020?
What time is the conference call for Pacira's Q3 results?
How can I participate in Pacira's conference call?
What products does Pacira BioSciences offer?
